Unlike traditional therapies, Avandia targets the underlying causes of type 2 diabetes – insulin resistance and associated beta-cell failure giving your type 2 diabetes patients sustained glycemic control, and more to feel good about

Sustained glycemic control/Years of benefits.

Click here to see the details and full-size version in the gallery

This ad and thousands more can be seen on the AdPharm gallery, the largest online pharmaceutical advertising gallery.

Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

nowosc -
rewolucja w walce z nadwaga
New -
A revolution in the fight against weight

Orlistat (marketed as a prescription under the trade name Xenical by Roche or over-the-counter as Alli by GlaxoSmithKline), also known as tetrahydrolipstatin, is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. It is intended for use in conjunction with a physician-supervised reduced-calorie diet. Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to simplicity and stability, orlistat rather than lipstatin was developed into an anti-obesity drug.

The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggests that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug. Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.

More on Wikipedia

Brand name: Alli
Generic name/category: Orlistat, Antiobesity drugs, Lactones
Company: GlaxoSmithKline Consumer Healthcare (GSK)
Country/Market: Poland, Europe
Indication(s)/use: obesity
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: single-page
Publication/Aired: Gazeta Farmaceutyczna – September 2009

To see all of this brand’s ads on AdPharm, click here

Alli, nueva solución para ayudarte a perder un 50% más de peso.
Alli, a new solution to help you lose 50% more weight.

Orlistat (marketed as a prescription under the trade name Xenical by Roche or over-the-counter as Alli by GlaxoSmithKline), also known as tetrahydrolipstatin, is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. It is intended for use in conjunction with a physician-supervised reduced-calorie diet. Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to simplicity and stability, orlistat rather than lipstatin was developed into an anti-obesity drug.

The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggests that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug. Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.

More on Wikipedia

Brand name: Alli
Generic name/category: Orlistat, Antiobesity drugs, Lactones
Company: GlaxoSmithKline Consumer Healthcare (GSK)
Country/Market: Spain, Europe
Indication(s)/use: obesity
Target: Consumers (DTC)
Medium: Print ad
Size/duration: single-page
Publication/Aired: Psychologies – August 2009

To see all of this brand’s ads on AdPharm, click here

To prevent and potentially reverse many of the symptoms of Type 1 Gaucher Disease
Cerezyme leads the way

Proven efficacy and safety for over 14 years

Brand name: Cerezyme
Generic name/category: Imiglucerase for injection
Company: Genzyme
Country/Market: USA, North America
Indication(s)/use: Gaucher’s Disease
Target: Healthcare Professionals (HCP)
Tagline: Leads the way
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – September 17, 2009